Who is sponsoring NCT03652857?

NCT03652857 is sponsored by Yongchang Zhang.

What drugs are being tested in NCT03652857?

Interventions in NCT03652857: Apatinib Combined With Vinorelbine.

What condition does NCT03652857 study?

NCT03652857 studies Advanced Non Small Cell Lung Cancer.

Is NCT03652857 still recruiting?

NCT03652857 is currently completed. Last updated 17 February 2020.

Last reviewed 2020-02-17 · How we verify

NCT03652857

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer

Completed Phase 2 Last updated 17 February 2020

What this trial tests

Phase 2 trial testing Apatinib Combined With Vinorelbine in Advanced Non Small Cell Lung Cancer in 30 participants. Completed in 31 December 2019.

Timeline

1 January 2017

Primary endpoint
30 November 2018

31 December 2019

Quick facts

Lead sponsor	Yongchang Zhang
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 January 2017
Primary completion	30 November 2018
Estimated completion	31 December 2019
Sites	1 location across China

Drugs / interventions tested

Apatinib Combined With Vinorelbine — full drug profile →

Conditions studied

Advanced Non Small Cell Lung Cancer — all drugs for Advanced Non Small Cell Lung Cancer →

Sponsor

Yongchang Zhang — full company profile →

Who can join

18 and older, any sex, with Advanced Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety and effectiveness of Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Posterior Advanced Non-small Cell Lung Cancer

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.
Zhang X, Xiong Y, Xia Q, Wu F, et al · · 2020 · cited 15× · PMID 32191330 · DOI 10.1001/jamanetworkopen.2020.1226

Verify or expand the search:

Other recruiting trials for Advanced Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06908993 — Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Trea · Phase 3 · recruiting
NCT05777603 — Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer · Phase 1 · recruiting
NCT06107374 — Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG · Phase 2 · recruiting
NCT06406166 — Lifei Xiaoji Wan in Treatment of Advanced NSCLC · NA · recruiting
NCT04886401 — Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC · recruiting

Other Yongchang Zhang trials

Trials by the same sponsor.

NCT03807102 — Trial of Tumor Vaccine Used for Adjuvant Therapy in Post Radical Operation Patients With Lung Cancer · Phase 1, PHASE2 · unknown
NCT04777175 — A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer · recruiting
NCT05530785 — Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT · NA · unknown
NCT04144608 — Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC · Phase 2 · completed
NCT06521034 — First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03652857 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yongchang Zhang
Last refreshed: 17 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03652857.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing